KMT2A and leukemia: The fact that the combination treatment had significantly higher effects in the reduction of the tumor burden in the animal models that the authors used suggests that the repurposing of fidaxomicin to target ABCC3 in leukemia acts synergistically with the de novo drugs to overcome chemoresistance in MLL-rearranged leukemia.